3-(4-Cyano-phenyl)-5-methoxycarbonylmethyl-4,5-dihydro-isoxazole-5-carboxylic acid methyl ester | 201005-03-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-Cyano-phenyl)-5-methoxycarbonylmethyl-4,5-dihydro-isoxazole-5-carboxylic acid methyl ester
• CAS: 201005-03-0
• 化学式: C₁₅H₁₄N₂O₅
• 分子量: 302.287
• InChiKey: COLFFFSGZNFIAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.16
• 重原子数：
  22.0
• 可旋转键数：
  4.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  97.98
• 氢给体数：
  0.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  3-(4-Cyano-phenyl)-5-methoxycarbonylmethyl-4,5-dihydro-isoxazole-5-carboxylic acid methyl ester 在 N-甲基吗啉 、 盐酸 、 lithium hydroxide 、 ammonium acetate 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-(4-amidinophenyl)-5-[(3-amidinophenyl)aminocarbonyl]-5-(carbomethoxymethyl)isoxazoline
  参考文献：
  名称：

  Bisbenzamidine isoxazoline derivatives as factor Xa inhibitors

  摘要：

  Factor Xa is an important serine protease in the blood coagulation cascade. It generates thrombin and holds the central position that links the intrinsic and extrinsic activation mechanism in the final common pathway of coagulation. Therefore, inhibition of factor Xa has potential therapeutic applications in the treatment of both arterial and venous thrombosis. We have designed and synthesized a series of bisbenzamidine isoxazoline derivatives as factor Xa inhibitors. The most potent compound in this series has a K-i of 18 nM against factor Xa. (C) 1997 The DuPont Merck Pharmaceutical Company. Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)10081-6
• 作为产物：
  描述：

  4-氰基苯甲醛 、 alkaline earth salt of/the/ methylsulfuric acid 在 sodium hypochlorite 、 羟胺 作用下， 以 四氢呋喃 、 吡啶 、 乙醇 为溶剂， 生成 3-(4-Cyano-phenyl)-5-methoxycarbonylmethyl-4,5-dihydro-isoxazole-5-carboxylic acid methyl ester
  参考文献：
  名称：

  Bisbenzamidine isoxazoline derivatives as factor Xa inhibitors

  摘要：

  Factor Xa is an important serine protease in the blood coagulation cascade. It generates thrombin and holds the central position that links the intrinsic and extrinsic activation mechanism in the final common pathway of coagulation. Therefore, inhibition of factor Xa has potential therapeutic applications in the treatment of both arterial and venous thrombosis. We have designed and synthesized a series of bisbenzamidine isoxazoline derivatives as factor Xa inhibitors. The most potent compound in this series has a K-i of 18 nM against factor Xa. (C) 1997 The DuPont Merck Pharmaceutical Company. Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)10081-6